deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04600921

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study (ERASE)

Ertugliflozin to Reduce Arrhythmic Burden in Implantable Cardioverter-defibrillators (ICD)/Cardiac Resynchronisation Therapy(CRT) patientS (ERASe-Trial) - a Phase III Study

Sponsor: Elisabethinen Hospital

Updated 14 times since 2020 Last updated: May 14, 2025 Started: Jun 24, 2021 Primary completion: Jun 23, 2023 Completion: Oct 18, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The feasibility (recruitment) of the high number of patients (402 patients with HFrEF or HFmrEF) was impossible due to the rapid increase in SGLT2 inhibitors in patients with heart failure.

Other Cardiac Resynchronization Therapy trials with similar outcome

Browse all Cardiac Resynchronization Therapy trials

A PHASE3 clinical study on Cardiac Resynchronization Therapy and Heart Failure With Mid Range Ejection Fraction, this trial is terminated or withdrawn. The trial is conducted by Elisabethinen Hospital and has accumulated 14 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Aug 2023 · 15 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

14 versions recorded
  1. Jun 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Jun 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

  5. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

Show 9 earlier versions
  1. May 2022 — Aug 2023 [monthly]

    Recruiting PHASE3

  2. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE3

  3. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  4. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  5. May 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

  6. Feb 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE3

  7. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  9. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Elisabethinen Hospital
  • General Hospital Linz
  • Klinik Ottakring
  • Klinikum Klagenfurt am Wörthersee
  • Landesklinkum Wiener Neustadt
  • Medical University Innsbruck
  • Medical University of Graz
  • Medical University of Vienna
Data source: Medical University of Graz

For direct contact, visit the study record on ClinicalTrials.gov .